following a full submission assessed under the end of life process:
nivolumab (Opdivo®) is accepted for use within NHSScotland.
Indication under review: in combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
In a phase III study of patients with previously untreated, unresectable MPM, overall survival was significantly longer in the nivolumab plus ipilimumab group compared with standard chemotherapy.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 07 February 2022